COLLAGEN CONTAINING OPHTHALMIC FORMULATION

26820-FF COLLAGEN CONTAINING OPHTHALMIC FORMULATION An ophthalmologically acceptable collagen containing aqueous composition is disclosed. The composition contains collagen and is a flowable liquid at temperatures below mammalian eye temperature (32.degree.C to 42.degree.C) and forms a gelled sustai...

Full description

Saved in:
Bibliographic Details
Main Authors SHEK, EFRAIM, FLEITMAN, JEFFREY C, LEUNG, DE MEI C, FU, CHERNGYI R
Format Patent
LanguageEnglish
French
Published 14.04.1991
Edition5
Subjects
Online AccessGet full text

Cover

Loading…
Abstract 26820-FF COLLAGEN CONTAINING OPHTHALMIC FORMULATION An ophthalmologically acceptable collagen containing aqueous composition is disclosed. The composition contains collagen and is a flowable liquid at temperatures below mammalian eye temperature (32.degree.C to 42.degree.C) and forms a gelled sustained release matrix after administration to the mammalian eye. The composition is comprised of ophthalmologically acceptable collagen material, a pharmaceutically active non-steroidal antiinflammatory drug, optionally an antibiotic, a buffer, a nonionic ethoxylated alkylphenol surfactant, a quaternary ammonium preservative, a tonicifier, a chelating agent, and optional excipients in an aqueous carrier. The collagen in the composition undergoes a change from a flowable liquid to a gelled matrix after the formulation is administered to the eye. The gelled matrix of the formulation traps and physically holds the drug in the matrix. When applied, the gel will remain in place in the cul-de-sac of the eye substantially longer than liquid formulations and will allow for a sustained release method of delivery of the drug to the eye. The drug release from the matrix and the drug half life are such that the formulation allows for once a day or even less frequent dosing which increases the convenience and improves patient compliance. 26820FF1 26820-FF
AbstractList 26820-FF COLLAGEN CONTAINING OPHTHALMIC FORMULATION An ophthalmologically acceptable collagen containing aqueous composition is disclosed. The composition contains collagen and is a flowable liquid at temperatures below mammalian eye temperature (32.degree.C to 42.degree.C) and forms a gelled sustained release matrix after administration to the mammalian eye. The composition is comprised of ophthalmologically acceptable collagen material, a pharmaceutically active non-steroidal antiinflammatory drug, optionally an antibiotic, a buffer, a nonionic ethoxylated alkylphenol surfactant, a quaternary ammonium preservative, a tonicifier, a chelating agent, and optional excipients in an aqueous carrier. The collagen in the composition undergoes a change from a flowable liquid to a gelled matrix after the formulation is administered to the eye. The gelled matrix of the formulation traps and physically holds the drug in the matrix. When applied, the gel will remain in place in the cul-de-sac of the eye substantially longer than liquid formulations and will allow for a sustained release method of delivery of the drug to the eye. The drug release from the matrix and the drug half life are such that the formulation allows for once a day or even less frequent dosing which increases the convenience and improves patient compliance. 26820FF1 26820-FF
Author LEUNG, DE MEI C
FLEITMAN, JEFFREY C
FU, CHERNGYI R
SHEK, EFRAIM
Author_xml – fullname: SHEK, EFRAIM
– fullname: FLEITMAN, JEFFREY C
– fullname: LEUNG, DE MEI C
– fullname: FU, CHERNGYI R
BookMark eNrjYmDJy89L5WTQcvb38XF0d_VTcPb3C3H09PP0c1fwD_AI8XD08fV0VnDzD_IN9XEM8fT342FgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8c6ORgZG5ibGxo6GxkQoAQADSyYH
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate FORMULE OPHTALMIQUE A BASE DE COLLAGENE
Edition 5
ExternalDocumentID CA2027433A1
GroupedDBID EVB
ID FETCH-epo_espacenet_CA2027433A13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:55:39 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CA2027433A13
Notes Application Number: CA19902027433
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19910414&DB=EPODOC&CC=CA&NR=2027433A1
ParticipantIDs epo_espacenet_CA2027433A1
PublicationCentury 1900
PublicationDate 19910414
PublicationDateYYYYMMDD 1991-04-14
PublicationDate_xml – month: 04
  year: 1991
  text: 19910414
  day: 14
PublicationDecade 1990
PublicationYear 1991
RelatedCompanies SYNTEX (U.S.A.) INC
RelatedCompanies_xml – name: SYNTEX (U.S.A.) INC
Score 2.4049923
Snippet 26820-FF COLLAGEN CONTAINING OPHTHALMIC FORMULATION An ophthalmologically acceptable collagen containing aqueous composition is disclosed. The composition...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title COLLAGEN CONTAINING OPHTHALMIC FORMULATION
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19910414&DB=EPODOC&locale=&CC=CA&NR=2027433A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ3NS8MwFMAfY4p606k4v-hBehCKXZu27lAkS7d10i-kk91Gs6Swyxyu4r_va-ymF72FBPIFL-_9Xt5LAO5cBOqFZ0rDKrgwSL-0DC5KaZDSdB5NzouFqP0dceKGU_I8c2YtWG5zYdQ7oZ_qcUSUqAXKe6XO6_WPEytQsZWbB77EqrenUe4HumjSxRAuekQPBv4wS4OU6Yz5jOrJi18zPrFtiqC0h1a0p5jtdVAnpax_a5TRMexn2NmqOoGWXHXgkG0_XuvAQdzcd2OxEb3NKdyzNIroeJhoLE1yOkkmyVhLszAPaYRbqSHNxdNIeZzOQBsNcxYaOOh8t8A5o7vp2efQRu6XF6BJxxKeJ5GICkKk7RRl3xJovbiCu6iHe13o_tnN5T9tV3D0He9EjB65hnb1_iFvULNW_FbtyRcBj3jg
link.rule.ids 230,309,783,888,25577,76883
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ3NT8IwFMBfCBrxpqgRP3cwO5gswtYNOCxmdBtDt46YYbiRde0SLkhkxn_fRwX0oremTfqVvL73e32vBbhzEKiLblsaZs6FQfqlaXBRSoOUbbvX5jwvxNrfkTAnmpCnqT2twXybC6PeCf1UjyOiRBUo75U6r5c_TixfxVauHvgcq94ew8z1dbFJF0O46BDdH7jBOPVTqlPqUk9nL-6a8YlleQhKe2hh9xQpvQ7WSSnL3xolPIL9MXa2qI6hJhdNaNDtx2tNOEg2991Y3Ije6gTuaRrH3jBgGk1Z5o3YiA21dBxlkRfjVmpIc8kkVh6nU9DCIKORgYPOdgucUW83PesM6sj98hw0aZui25VIRDkh0rLzsm8KtF4cwR3Uw50WtP7s5uKftltoRFkSz-IRe76Ew-_YJ2J0yBXUq_cPeY1atuI3an--ANOMe9A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=COLLAGEN+CONTAINING+OPHTHALMIC+FORMULATION&rft.inventor=SHEK%2C+EFRAIM&rft.inventor=FLEITMAN%2C+JEFFREY+C&rft.inventor=LEUNG%2C+DE+MEI+C&rft.inventor=FU%2C+CHERNGYI+R&rft.date=1991-04-14&rft.externalDBID=A1&rft.externalDocID=CA2027433A1